These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 32060956)

  • 1. Medicinal chemistry strategies toward host targeting antiviral agents.
    Ji X; Li Z
    Med Res Rev; 2020 Sep; 40(5):1519-1557. PubMed ID: 32060956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses.
    He Y; Zhou J; Gao H; Liu C; Zhan P; Liu X
    Eur J Med Chem; 2024 Feb; 265():116069. PubMed ID: 38160620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
    Baugh JM; Garcia-Rivera JA; Gallay PA
    Antiviral Res; 2013 Nov; 100(2):555-61. PubMed ID: 24091203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.
    Zeisel MB; Crouchet E; Baumert TF; Schuster C
    Viruses; 2015 Nov; 7(11):5659-85. PubMed ID: 26540069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.
    Zeisel MB; Lupberger J; Fofana I; Baumert TF
    J Hepatol; 2013 Feb; 58(2):375-84. PubMed ID: 23041307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases.
    Hajjo R; Sabbah DA; Abusara OH; Kharmah R; Bardaweel S
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini-Review.
    Liu M; Peng W; Ji X
    Mini Rev Med Chem; 2024 Aug; ():. PubMed ID: 39185650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C.
    Gerold G; Pietschmann T
    Curr Hepat Rep; 2013; 12(4):200-213. PubMed ID: 32214912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
    Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
    Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
    Xiao F; Fofana I; Thumann C; Mailly L; Alles R; Robinet E; Meyer N; Schaeffer M; Habersetzer F; Doffoël M; Leyssen P; Neyts J; Zeisel MB; Baumert TF
    Gut; 2015 Mar; 64(3):483-94. PubMed ID: 24848265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparing for the next viral threat with broad-spectrum antivirals.
    Karim M; Lo CW; Einav S
    J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the pros and cons of the use of host-targeted agents against hepatitis C?
    Pawlotsky JM
    Antiviral Res; 2014 May; 105():22-5. PubMed ID: 24583032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
    von Hahn T; Ciesek S; Manns MP
    Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical Approaches for Treatment of Hepatitis C virus.
    Milani A; Basimi P; Agi E; Bolhassani A
    Curr Pharm Des; 2020; 26(34):4304-4314. PubMed ID: 32386486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
    Crouchet E; Wrensch F; Schuster C; Zeisel MB; Baumert TF
    Therap Adv Gastroenterol; 2018; 11():1756284818759483. PubMed ID: 29619090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current progress in antiviral strategies.
    Lou Z; Sun Y; Rao Z
    Trends Pharmacol Sci; 2014 Feb; 35(2):86-102. PubMed ID: 24439476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses.
    Komarasamy TV; Adnan NAA; James W; Balasubramaniam VR
    PLoS Negl Trop Dis; 2022 Apr; 16(4):e0010291. PubMed ID: 35482672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.
    Wangen C; Raithel A; Tillmanns J; Gege C; Herrmann A; Vitt D; Kohlhof H; Marschall M; Hahn F
    Antiviral Res; 2024 Jan; 221():105769. PubMed ID: 38056603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.